A new HIV-1 receptor may become a target for the development of new AIDS drugs

the National Institutes of Health's Arthos et alreport that a new human immunodeficiency virus 1 (HIV-1) receptor, the integrated alpha 4 beta 7 (integrin alpha 4 beta 7), was found to guide HIV into the digestive tract after it entered the bodyThe discovery of this HIV receptor may explain why the digestive tract is the main site of HIV replication and provides a direction for the development of new HIV drugs(Nat Immunol, 10 February 2008)infection with HIV-1 can cause the virus to spread in the lymphatic tissue associated with the digestive tract, which in turn causes a significant reduction in gastrointestinal CD4 plus T cells, resulting in an immune deficiency in patientsIntegrator alpha4 beta7 is a normal component of human cells, located in the mucous membrane of the digestive tract, and is the peripheral T-cell nesting receptorThe migration of lymphocytes to the lymphatic tissue of the gastrointestinal tract is mediated by integrator alpha4 beta7Arthos and other studies have found that HIV-1's envelope protein gp120 binds to activated integrator alpha4 beta7, which is mediated by a tripeptide located on the gp120 V2 ring, whose base sequence is similar to that of a ligator alpha4 beta7 in the human bodyIn CD4 plus T cells, the linking of gp120 to integrator alpha4 beta 7 allows lymphocyte function-related antigen-1 (LFA-1) to be activated quickly, while LFA-1 participates in the establishment of the Virausss, which causes HIV-1 to be effectively splattered between cellsA variety of HIV receptors have been found, the most important of which is the CD4 molecule located on T cells, which was discovered in 1984Two other important receptors, CCR5 and CXCR4, were discovered in 1996Among them, CCR5 is the normal component of human cells, it is HIV invasion of the "gate god", a very small number of people due to genetic mutations caused by THE lack of CCR5, even if they are often exposed to HIV will not be infectedThe new HIV receptor may be a target for the development of new HIV drugs, the researchers saidLast year, for example, the FDA approved a new drug for AIDS treatment, maraviroc, which blocks CCR5Several drugs that block the receptors of the integratant alpha 4 beta7 are currently undergoing research to treat autoimmunedisease, and Arthos believes they should also be studied for potential anti-HIV efficacy (Nan Chang)